Capricor Therapeutics (CAPR) Expected to Announce Earnings on Thursday

Capricor Therapeutics (NASDAQ:CAPR) is expected to be posting its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect Capricor Therapeutics to post earnings of ($0.31) per share and revenue of $9.87 million for the quarter.

Capricor Therapeutics Price Performance

CAPR stock opened at $14.46 on Thursday. The company has a market cap of $657.50 million, a P/E ratio of -13.64 and a beta of 4.08. Capricor Therapeutics has a 1 year low of $3.52 and a 1 year high of $23.40. The stock’s fifty day moving average price is $14.34 and its 200-day moving average price is $13.57.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Cantor Fitzgerald raised their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research report on Thursday, January 2nd. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.